Plasma Short‐Chain Fatty Acids in Patients With Parkinson's Disease
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: Short‐chain fatty acids are exclusively produced by gut microbiota and are reduced in feces of patients with Parkinson's disease (PD). The objective of this study was to conduct a case–control study on peripheral concentration of short‐chain fatty acids based on evidence of pathologic changes in the blood–brain barrier in PD and the possible role of short‐chain fatty acids in blood–brain barrier permeability. Methods: The plasma short‐chain fatty acid concentration was measured in 38 PD and 33 normal controls using gas chromatography. The clinical characteristics of patients with PD and controls were evaluated, and dietary information was obtained using a food frequency questionnaire. Short‐chain fatty acid concentrations were further compared after adjusting for age, sex, and significant food frequency questionnaire items. Results: The concentrations of acetate, propionate, and butyrate did not differ between patients with PD and controls in unadjusted comparison. Dietary intakes of fibers, carbohydrates, lipids (total and fatty acids), and proteins did not differ between groups. After correction of covariates, acetic acid concentration was higher in patients with PD than in controls (116.47 ± 16.83 vs 108.20 ± 18.37 μmol/L; P = 0.010). In correlation analyses, acetic acid concentration was positively correlated (R = 0.374, P = 0.021) with age, propionic acid concentration was negatively correlated with UPDRS part III score (R = −0.376, P = 0.020) and use of entacapone (R = −0.325, P = 0.047), and butyric acid concentration was correlated with monoamine oxidase inhibitor use (R = 0.382, P = 0.018) and anticholinergic use (R = −0.385, P = 0.024). Conclusions: Plasma short‐chain fatty acids were paradoxically increased in PD and were associated with disease severity and antiparkinsonian medications. Further studies are warranted to elucidate the relationships of gut dysbiosis and inflammation with plasma short‐chain fatty acids. © 2020 International Parkinson and Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism
Morrison, D. J., & Preston, T. (2016) · Gut Microbes · doi:10.1080/19490976.2015.1134082 · Cited by 3,781 · cited 1×
“the gut and transported to the liver via the portal venous system, and some SCFAs enter systemic circulation.(7) A”
BackgroundGut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Host microbiota constantly control maturation and function of microglia in the CNS
Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4030 · Cited by 3,569
The gut microbiota influences blood-brain barrier permeability in mice
Braniste, V., Al-Asmakh, M., Kowal, C., Anuar, F., Abbaspour, A., Tóth, M., Korecka, A., Bakocevic, N., Ng, L. G., Kundu, P., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009759 · Cited by 2,530
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172 · cited 11×
“In this study, we measured the concentration of plasma SCFAs as the first step of investigating their role in PD.”
BackgroundInfluentialForsyth, C. B., Shannon, K. M., Kordower, J. H., Voigt, R. M., Shaikh, M., Jaglin, J. A., Estes, J. D., Dodiya, H. B., & Keshavarzian, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0028032 · Cited by 974
Hill‐Burns, E. M., Debelius, J. W., Morton, J. T., Wissemann, W. T., Lewis, M. R., Wallen, Z. D., Peddada, S. D., Factor, S. A., Molho, E., Zabetian, C. P., et al. (2017) · Movement Disorders · doi:10.1002/mds.26942 · Cited by 874 · cited 14×
“In this study, we measured the concentration of plasma SCFAs as the first step of investigating their role in PD.”
BackgroundResultInfluentialBlood–brain barrier dysfunction in parkinsonian midbrain in vivo
Kortekaas, R., Leenders, K. L., van Oostrom, J. C. H., Vaalburg, W., Bart, J., Willemsen, A. T. M., & Hendrikse, N. H. (2005) · Annals of Neurology · doi:10.1002/ana.20369 · Cited by 733
Colonic inflammation in Parkinson's disease
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.-M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.007 · Cited by 627
Heintz‐Buschart, A., Pandey, U., Wicke, T., Sixel‐Döring, F., Janzen, A., Sittig‐Wiegand, E., Trenkwalder, C., Oertel, W. H., Mollenhauer, B., & Wilmes, P. (2018) · Movement Disorders · doi:10.1002/mds.27105 · Cited by 554 · cited 11×
“In this study, we measured the concentration of plasma SCFAs as the first step of investigating their role in PD.”
BackgroundInfluentialPathological α‐synuclein in gastrointestinal tissues from prodromal Parkinson disease patients
Stokholm, M. G., Danielsen, E. H., Hamilton‐Dutoit, S. J., & Borghammer, P. (2016) · Annals of Neurology · doi:10.1002/ana.24648 · Cited by 415
Striatal Blood–Brain Barrier Permeability in Parkinson'S Disease
Gray, M. T., & Woulfe, J. M. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.32 · Cited by 409
Production and utilization of acetate in mammals
Knowles, S. E., Jarrett, I. G., Filsell, O. H., & Ballard, F. J. (1974) · Biochemical Journal · doi:10.1042/bj1420401 · Cited by 348
Schwiertz, A., Spiegel, J., Dillmann, U., Grundmann, D., Bürmann, J., Faßbender, K., Schäfer, K.-H., & Unger, M. M. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.022 · Cited by 318
6-Hydroxydopamine-induced alterations in blood-brain barrier permeability
Carvey, P. M., Zhao, C. H., Hendey, B., Lum, H., Trachtenberg, J., Desai, B. S., Snyder, J., Zhu, Y. G., & Ling, Z. D. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04281.x · Cited by 218
Pouteau, E., Meirim, I., Métairon, S., & Fay, L. (2001) · Journal of Mass Spectrometry · doi:10.1002/jms.181 · Cited by 77 · cited 1×
“SCFA concentration was calculated relative to that of the IS by the peak height ratio method.(21,22)”
MethodA controversy on the role of short-chain fatty acids in the pathogenesis of Parkinson's disease
Mulak, A. (2018) · Movement Disorders · doi:10.1002/mds.27304 · Cited by 45 · cited 8×
“DOI: 10.1002/mds.28016 Movement Disorders, Vol. 35, No. 6, 2020 1021 patients, suggesting derangement of the intestinal environment.8 Moreover, previous studies repeatedly found that the abundances of SCFA-producing microbiota, such as Prevotellaceae and Lachnospiraceae, was decreased in PD patients.3-5,8,9 Although t…”
BackgroundInfluential
Cited by
The microbiome–gut–brain axis in Parkinson disease — from basic research to the clinic
Tan, A. H., Lim, S. Y., & Lang, A. E. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00681-2 · Cited by 392
Chen, S.-J., Chen, C.-C., Liao, H.-Y., Lin, Y.-T., Wu, Y.-W., Liou, J.-M., Wu, M.-S., Kuo, C.-H., & Lin, C.-H. (2022) · Neurology · doi:10.1212/wnl.0000000000013225 · Cited by 269
“A case–control study in a Korean population also showed that plasma acetic acid was increased in patients with PD even though the level did not correlate with motor symptom severity.(16) Recent evidence also revealed that concentrations of SCFAs are elevated in saliva and urine in patients with PD compared to the gene…”
BackgroundResultShort-chain fatty acid: An updated review on signaling, metabolism, and therapeutic effects
Rekha, K., Venkidasamy, B., Samynathan, R., Nagella, P., Rebezov, M., Khayrullin, M., Ponomarev, E., Bouyahya, A., Sarkar, T., Shariati, M. A., et al. (2024) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2124231 · Cited by 162
“The authors concluded that plasma SCFAs were increased in Parkinson’s disease subjects which are associated with disease severity, and suggested that alteration in gut microbiota and decreased fecal SCFA due to intestinal wall leakage need to be elucidated in the near future (Shin et al. 2020).”
BackgroundNeuroprotective effects of short-chain fatty acids in MPTP induced mice model of Parkinson's disease
Hou, Y., Li, X., Liu, C., Zhang, M., Zhang, X., Ge, S., & Zhao, L. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111376 · Cited by 101
Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101347 · Cited by 101
Metadata
- Authors
- Shin, C., Lim, Y., Lim, H., & Ahn, T.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2020-03-10
- Volume
- 35
- Issue
- 6
- Pages
- 1021-1027
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W3011004494
- Cited by
- 116
- References
- 18
- FWCI
- 6.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.